hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06338748, orgStudyIdInfo id: 24-157, briefTitle: Accuracy of the Dexcom G7 Continuous Glucose Monitoring System Following Cardiac Surgery, acronym: DexcomG7, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-06-01, completionDateStruct date: 2025-12-01, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: The Cleveland Clinic, class: OTHER, collaborators name: DexCom, Inc., descriptionModule briefSummary: This is a prospective longitudinal study to study the agreement between a continuous glucose monitoring system (CGMS) versus current blood glucose monitoring. Subjects in this study will have their blood glucose measured regularly every 1-3 hours with current methods in the Cardiovascular Intensive Care Unit (CVICU), and by Point of Care (POC) fingerstick glucose using the Accucheck Inform II on the regular floors, and the CGMS reading at the same time will be captured. Subjects will have measurements taken throughout their stay in the CVICU and on the regular floors. Agreement and correlation between systems, as well as errors, will be calculated., conditionsModule conditions: Continuous Glucose Monitoring, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Patients undergoing heart surgery at the Cleveland Clinic (main campus) who would normally be tested for high sugar levels by poking a finger and using a test strip., primaryPurpose: OTHER, maskingInfo masking: NONE, maskingDescription: The study will involve using blinded Dexcom G7 continuous glucose monitoring (CGM) devices, enrollmentInfo count: 28, type: ESTIMATED, armsInterventionsModule interventions name: Continuous glucose monitor (CGM) Dexcom G7 used in blinded mode, outcomesModule primaryOutcomes measure: Compare accuracy of glucose readings obtained from Dexcom G7 compared to blood glucose obtained from arterial blood gas (ABG) or peripheral/central venous catheter or fingerstick point of care (POC) while patients are in the CVICU, primaryOutcomes measure: Compare accuracy of glucose readings obtained from Dexcom G7 compared to blood glucose obtained from fingerstick POC glucose when patients are on the regular floors, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Cleveland Clinic Foundation, city: Cleveland, state: Ohio, zip: 44195, country: United States, contacts name: Kimberly Jenkins, role: CONTACT, phone: 216-445-4791, email: jenkink@ccf.org, contacts name: Kimberly Jenkins, role: CONTACT, phone: (216) 445-4791, email: jenkink@ccf.org, geoPoint lat: 41.4995, lon: -81.69541, hasResults: False
protocolSection identificationModule nctId: NCT06338735, orgStudyIdInfo id: 14540, briefTitle: Ultra-High Frequency Ultrasonography in Sjögren's Syndrome, acronym: UltraSjögren, statusModule overallStatus: RECRUITING, startDateStruct date: 2016-01-11, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2030-12, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: University of Pisa, class: OTHER, descriptionModule briefSummary: Patients diagnosed with a diagnosis of Sjogren's syndrome performed according to the ACR/EULAR criteria will be included in the study. Sjogren's syndrome diagnosis will be performed following a complete diagnostic work-up involving rheumatologic assessment, glandular functional tests, and blood testing for anti-Ro(SSA) antibodies. Conventional ultrasonography of major salivary glands and ultra-high frequency ultrasonography (70 MHz) of minor salivary glands will be performed, and the scans assessed using the Outcome Measures in Rheumatology (OMERACT) scoring system (Score 0 normal glandular tissue, Score 1 mild glandular alteration, fine echogenicity or diffuse hypo-echogenicity, Score 2 moderate glandular alteration and focal hypoechoic areas with partial conservation of normal parenchyma, Score 3 diffuse presence of hypoechoic areas in the absence of normal glandular parenchyma with glandular fibrosis. Focus Score will be assessed following biopsy of minor salivary glands., conditionsModule conditions: Sjogren's Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 800, type: ESTIMATED, armsInterventionsModule interventions name: Ultra-High Frequency Ultrasound scan of minor salivary glands, outcomesModule primaryOutcomes measure: OMERACT score, primaryOutcomes measure: Correspondence between ultrasonography and histology, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Pisa, status: RECRUITING, city: Pisa, zip: 56126, country: Italy, contacts name: Rossana Izzetti, role: CONTACT, phone: +39050993037, email: rossana.izzetti@unipi.it, contacts name: Rossana Izzetti, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 43.70853, lon: 10.4036, hasResults: False
protocolSection identificationModule nctId: NCT06338722, orgStudyIdInfo id: 23-397, briefTitle: Making it Work Program for Systemic Sclerosis, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-08, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2024-09-30, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: University of New Mexico, class: OTHER, descriptionModule briefSummary: The purpose of this clinical trial is to see if an online intervention program for people with Systemic Sclerosis (scleroderma) helps keep people in the workforce and increase self-confidence in dealing with challenges at work. The program is called Making it Work Systemic Sclerosis.Researchers will compare a group who gets the program to a group who will get the program at a later point in time (wait list control group) to see if self-confidence in dealing with work challenge gets better.People in the Making it Work group will complete questionnaires and attend one 2 hour meetings each week for 5 weeks and meet with an occupational therapist and vocational counselor. People in the wait list control group will complete the questionnaires and participate in the program at a later point in time., conditionsModule conditions: Scleroderma, Systemic, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Intervention receives the Making it work program Wait list Control receives usual care but will be offered the program after the intervention groups finish, primaryPurpose: TREATMENT, maskingInfo masking: NONE, maskingDescription: People will know what group they are in when they are invited to attend the intervention sessions, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Making it Work Systemic Sclerosis, outcomesModule primaryOutcomes measure: Job Related Self-efficacy Scale, primaryOutcomes measure: Job Self-Efficacy Scale, secondaryOutcomes measure: Work Productivity and Activity Impairment Questionnaire Specific Health Problem Subscale, secondaryOutcomes measure: The Work Instability Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 67 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of New Mexico, status: RECRUITING, city: Albuquerque, state: New Mexico, zip: 87131-0001, country: United States, contacts name: Janet L Poole, PhD, role: CONTACT, phone: 505-272-8276, email: jpoole@salud.unm.edu, geoPoint lat: 35.08449, lon: -106.65114, hasResults: False
protocolSection identificationModule nctId: NCT06338670, orgStudyIdInfo id: CLTD5839, briefTitle: Clinical Performance of the Osia 3 Sound Processor Compared With the Osia 2 Sound Processor in Adult Osia Implant Users, acronym: RECONNECT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-08, primaryCompletionDateStruct date: 2024-11-22, completionDateStruct date: 2024-11-22, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Cochlear, class: INDUSTRY, collaborators name: Avania, descriptionModule briefSummary: This study aims to investigate the clinical performance of the Osia 3 Sound Processor in comparison to the Osia 2 Sound Processor in adults with mixed or conductive hearing loss or single-sided deafness implanted with an Osia implant. Participants will attend four study visits, where they will complete various hearing assessments using the Osia sound processors., conditionsModule conditions: Hearing Loss, Mixed Conductive-Sensorineural, conditions: Hearing Loss, Conductive, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Within-subject, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: Cochlear Osia 3 Sound Processor, interventions name: Cochlear™ Osia® 2 Sound Processor, outcomesModule primaryOutcomes measure: Change (within subject) in speech reception threshold in noise with fixed noise level at 65 dB SPL, primaryOutcomes measure: Change (within subject) in word recognition score in quiet measured at 65 dB SPL, primaryOutcomes measure: Change (within subject) in aided thresholds in sound field measured at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0 and 8.0 kHz, primaryOutcomes measure: Change (within subject) in the subjective rating of different aspects of sound when listening to sound clips, primaryOutcomes measure: Percentage of participants who preferred Osia 3 over Osia 2 sound processor, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The HEARing CRC, city: Melbourne, state: Victoria, zip: 3053, country: Australia, contacts name: Robert Cowan, role: CONTACT, phone: +61418780198, email: r.cowan@unimelb.edu.au, geoPoint lat: -37.814, lon: 144.96332, hasResults: False
protocolSection identificationModule nctId: NCT06338644, orgStudyIdInfo id: HelwanUY, briefTitle: Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients., acronym: Palbociclib, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2025-09-01, completionDateStruct date: 2026-09-01, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Helwan University, class: OTHER, descriptionModule briefSummary: Cyclin-dependent kinase (CDK) 4/6 inhibitors are a class of agents recently introduced in the clinic for the treatment of advanced hormone receptor-positive (HR+) and HER2-negative (HER2-) BC. Palbociclib, ribociclib and abemaciclib have all been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency among other regulatory bodies, conditionsModule conditions: Hormone-receptor-positive Breast Cancer, conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, conditions: Metastatic Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Palbociclib, outcomesModule primaryOutcomes measure: 1-year Progression free survival (PFS), secondaryOutcomes measure: Neutropenia, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06338618, orgStudyIdInfo id: 1532-N-23, briefTitle: Manual Therapy in Metabolic Liver Disease, acronym: OSTEO-EHMet, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-03, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-08, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: University of Seville, class: OTHER, descriptionModule briefSummary: Hepatic steatosis is a disease that is becoming more common in our society; approximately 40% of the population suffers from non-alcoholic fatty liver. The beneficial effect of manual therapy for the treatment of viscera dysfunctions such as the stomach or colon is known. The objective of this study is to demonstrate the anti-inflammatory effects of visceral manual therapy in patients with metabolic liver disease associated with non-alcoholic fatty liver., conditionsModule conditions: NAFLD, Non-alcoholic Fatty Liver Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 42, type: ESTIMATED, armsInterventionsModule interventions name: liver treatment protocol, outcomesModule primaryOutcomes measure: Hepatic steatosis index, secondaryOutcomes measure: FIB-4 index, secondaryOutcomes measure: NAFLD-fibrosis index, secondaryOutcomes measure: HOMA index, secondaryOutcomes measure: TyG index, secondaryOutcomes measure: Change from baseline in algometry, secondaryOutcomes measure: Visual analogue Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Universitary Hospital Juan Ramón Jiménez, status: RECRUITING, city: Huelva, zip: 21005, country: Spain, contacts name: Javer Carrasco Sánchez, Dr, role: CONTACT, phone: 682289772, email: fjcarrascos@icloud.com, geoPoint lat: 37.26638, lon: -6.94004, hasResults: False
protocolSection identificationModule nctId: NCT06338605, orgStudyIdInfo id: MEC-2023-0715, briefTitle: Evaluating the Incidence of Pseudo-Acute Kidney Injuries in Patients With Metastatic Breast Cancer on CDK4/6 Inhibitors Trough Cystatin C Analysis, acronym: CYSTATINcDK4/6, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-12-12, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Erasmus Medical Center, class: OTHER, descriptionModule briefSummary: CDK4/6 inhibitors have led to an improvement of both progression free survival (PFS) and overall survival (OS) in patients with advanced estrogen positive (ER+)/HER2- breast cancer when applied in the first or second line of treatment. Despite the advantages of CDK4/6 inhibitors, these medications can lead to adverse effects. One of the adverse events observed across all types of CDK4/6 inhibitors is an elevation in creatinine levels. An elevation in plasma creatinine during treatment with abemaciclib is not always indicative of a reduction in renal function; it can also be attributed to the inhibition of active tubular secretion of creatinine. This phenomenon is known as pseudo acute kidney injury (pseudo-AKI).The incidence of pseudo-AKI in patients using CDK4/6 inhibitors is currently unknown. A method to distinguish pseudo-AKI from AKI is measuring the level of an alternative filtration marker in blood, for example cystatin C. Cystatin C is also filtered at the glomerulus but not secreted intro the renal tubulus or reabsorbed into the bloodstream. Also, there is no affection by muscle mass or diet. In this study the investigators will explore the incidence of both AKI and pseudo-AKI in patients who are treated with CDK4/6 inhibitor treatment by assessing both creatinine and cystatin C in plasma., conditionsModule conditions: Advanced Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: no intervention, observational study of AKI under CDK4/6 inhibitor treatment, outcomesModule primaryOutcomes measure: Pseudo-AKI in patients on CDK4/6 inhibitors, secondaryOutcomes measure: Pseudo-AKI in patients on CDK4/6 inhibitors per drug, secondaryOutcomes measure: AKI in patients, secondaryOutcomes measure: Influencing factors cystatin C levels, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Erasmus Medical Center, city: Rotterdam, country: Netherlands, geoPoint lat: 51.9225, lon: 4.47917, hasResults: False
protocolSection identificationModule nctId: NCT06338592, orgStudyIdInfo id: UUtah_00153806, briefTitle: The MyLungHealth Study Protocol: Engaging Patients to Enable Interoperable Lung Cancer Decision Support at Scale, acronym: MyLungHealth, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-28, primaryCompletionDateStruct date: 2025-03-27, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: University of Utah, class: OTHER, descriptionModule briefSummary: Early lung cancer screening (LCS) through low-dose computed tomography (LDCT) is crucial but underused due to various barriers, including incomplete or inaccurate patient smoking data in the electronic health record and limited time for shared decision-making. The objective of this trial is to investigate a patient-centered intervention, MyLungHealth, delivered through the patient portal. The intervention is designed to improve LCS rates through increased identification of eligible patients and informed decision making., conditionsModule conditions: Lung Cancer, conditions: Lung Neoplasms/Diagnosis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This is a patient randomized trial that includes two sub-studies, with 2 arms each., primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 42415, type: ESTIMATED, armsInterventionsModule interventions name: MyLungHealth, interventions name: DecisionPrecision+, outcomesModule primaryOutcomes measure: Study 1 primary outcome: Percentage of participants identified as eligible for LCS., primaryOutcomes measure: Study 2 primary outcome: Percentage of participants for whom LDCT was ordered., secondaryOutcomes measure: Study 1 secondary outcome: Percentage of participants for whom LDCT was ordered., secondaryOutcomes measure: Study 1 secondary outcome: Percentage of participants for whom LDCT was completed., secondaryOutcomes measure: Study 2 secondary outcome: Percentage of participants for whom LDCT was completed., secondaryOutcomes measure: Study 2 secondary outcome: Percentage of participants for whom LCS care gap was closed., eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 79 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: NYU Langone Health, status: RECRUITING, city: New York, state: New York, zip: 10016, country: United States, contacts name: Devin Mann, MD, role: CONTACT, email: devin.mann@nyulangone.org, contacts name: Devin Mann, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 40.71427, lon: -74.00597, locations facility: University of Utah Health, status: RECRUITING, city: Salt Lake City, state: Utah, zip: 84112, country: United States, contacts name: Kensaku Kawamoto, MD, PhD, MHS, role: CONTACT, email: kensaku.kawamoto@utah.edu, contacts name: Kensaku Kawamoto, MD, PhD, MHS, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 40.76078, lon: -111.89105, hasResults: False
protocolSection identificationModule nctId: NCT06338579, orgStudyIdInfo id: 2023PPRC04, secondaryIdInfos id: 2023-A01763-42, type: OTHER, domain: IDRCB, briefTitle: Overview of Self-medication Among French Navy Personnel, acronym: AutoMMaN, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Direction Centrale du Service de Santé des Armées, class: OTHER, descriptionModule briefSummary: The goal of this cross-sectional descriptive observational study is to assess the extent of self-medication among the crews of surface ships at the Toulon naval base. This study could include healthy volunteers, or participants with well-controlled chronic pathologies enabling them to be fit for embarkation, who are currently being deployed for at least 4 weeks on a surface ship at the naval base.Participants will tick and complete a questionnaire (between 15 and 30 minutes) after 4 consecutive weeks on the ship., conditionsModule conditions: Self Medication, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 800, type: ESTIMATED, armsInterventionsModule interventions name: Questionnaire, outcomesModule primaryOutcomes measure: percentage of patients who have self-medication, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06338566, orgStudyIdInfo id: 2021PPRC10, secondaryIdInfos id: 2023-A01975-40, type: OTHER, domain: IDRCB, briefTitle: Prospective Follow-up of the Results of Nail Arthrodesis of the Ankle, acronym: PROCLOU, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Direction Centrale du Service de Santé des Armées, class: OTHER, descriptionModule briefSummary: The goal of this prospective, single-center observational study is to describe the functional outcome of the surgical procedure in patient who undergone transplanted centromedullary nailing in the septic setting.Patients will be asked to complete a questionnaire during follow-up consultations., conditionsModule conditions: Ankle Fractures, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Follow-up, outcomesModule primaryOutcomes measure: bony outcome of transcalcaneal nailing, secondaryOutcomes measure: functional result of the procedure, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False